Rhythm Pharmaceuticals, Inc.
RYTM
$93.72
$2.412.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 83.81% | 36.87% | 54.28% | 66.80% | 25.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.81% | 36.87% | 54.28% | 66.80% | 25.94% |
| Cost of Revenue | 96.19% | 26.80% | 43.65% | 88.09% | 29.96% |
| Gross Profit | 82.25% | 37.87% | 55.66% | 64.40% | 25.46% |
| SG&A Expenses | 62.69% | 50.75% | 48.19% | 26.18% | 13.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.11% | 25.55% | 34.76% | 34.85% | 8.51% |
| Operating Income | -11.40% | -14.08% | -19.98% | -11.90% | 1.02% |
| Income Before Tax | -11.49% | -9.58% | -20.03% | -45.66% | 64.97% |
| Income Tax Expenses | 581.25% | 65.56% | 132.27% | -29.65% | -73.33% |
| Earnings from Continuing Operations | -12.41% | -9.73% | -21.23% | -44.55% | 64.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.41% | -9.73% | -21.23% | -44.55% | 64.99% |
| EBIT | -11.40% | -14.08% | -19.98% | -11.90% | 1.02% |
| EBITDA | -11.77% | -14.48% | -20.34% | -12.05% | 0.98% |
| EPS Basic | -3.59% | -0.79% | -11.52% | -36.96% | 65.72% |
| Normalized Basic EPS | -3.43% | -0.91% | -10.91% | -9.02% | 3.16% |
| EPS Diluted | -3.59% | -0.79% | -11.52% | -36.96% | 65.72% |
| Normalized Diluted EPS | -3.43% | -0.91% | -10.91% | -9.02% | 3.16% |
| Average Basic Shares Outstanding | 7.79% | 8.57% | 8.23% | 4.38% | 4.85% |
| Average Diluted Shares Outstanding | 7.79% | 8.57% | 8.23% | 4.38% | 4.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |